Innocuité de l'Ixekizumab chez les patients atteints de rhumatisme psoriasique : Données de quatre essais cliniques avec plus de 2000 années-patients de traitement
doi: 10.1136/annrheumdis-2021-222027
This analysis aimed to report the safety profile of ixekizumab for the PsA SPIRIT programme. The overall safety profile and tolerability of ixekizumab are consistent with the previously known safety profile in patients with PsA.